Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02591264

Enrollment

120

Registered

2015-10-29

Start date

2015-11-30

Completion date

2016-11-30

Last updated

2015-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Thrombosis

Brief summary

The aim of this study is to determine the role of human neutrophil peptide-1 to 3 in the occurrence of periprocedural myocardial infarction.

Interventions

OTHERBlood sample

Blood sample drawn from participants for analysis of neutrophil peptide level

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Troponin negative patients * Stable angina * Unstable angina * Positive screening tests

Exclusion criteria

* Troponin positive * Technical failure of procedure * Hemodynamic unstability

Design outcomes

Primary

Measure	Time frame	Description
Human Neutrophil Peptide Level	Two hours	Laboratory analysis and measurement of Human Neutrophil Peptide-1 to 3 levels

Countries

Israel

Contacts

Primary ContactRami Abu Fanne, MD, PhD

ramia@hadassah.org.il972-50-3573694

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026